discoveri
smallpox
vaccin
edward
jenner
year
ago
defin
event
develop
vaccinolog
jenner
found
immunis
less
virul
antigen
relat
cowpox
viru
protect
virul
smallpox
viru
follow
oneanda
halfcenturi
vaccinolog
scienc
becam
firmli
establish
basic
principl
develop
worldwid
erad
smallpox
togeth
remark
reduct
import
infecti
diseas
human
polio
diphtheria
tetanu
pertussi
measl
mump
underlin
feasibl
util
vaccin
econom
benefit
prevent
control
final
extirp
infecti
diseas
andr
veterinari
medicin
vaccinolog
address
wider
spectrum
challeng
includ
develop
cost
effect
approach
prevent
control
infecti
anim
diseas
consid
anim
welfar
focus
decreas
product
cost
anim
use
food
sham
addit
mass
vaccin
programm
help
significantli
lower
consumpt
veterinari
drug
includ
antibiot
vaccin
also
led
reduc
neg
environment
impact
elimin
chemic
residu
product
milk
egg
meat
product
loss
caus
ill
avoid
emil
behr
shibasaburo
kitasato
develop
principl
serum
therapi
found
immun
diphtheria
tetanu
toxin
result
presenc
substanc
blood
call
antibodi
behr
kitasato
also
abl
transfer
immun
immunolog
anim
use
serum
anim
treat
nonleth
dose
crude
toxin
prepar
behr
kitasato
earli
pioneer
day
paul
ehrlich
discov
antibodi
could
act
magic
bullet
target
cancer
cell
ehrlich
later
protein
sequenc
structur
antibodi
well
structur
sequenc
gene
code
elucid
use
mous
hybridoma
gener
stabl
fusion
immortalis
myeloma
cell
b
cell
immunis
mice
provid
highli
specif
monoclon
antibodi
could
use
therapi
kohler
milstein
mous
antibodi
initi
use
human
therapi
interact
well
enough
differ
receptor
type
result
ineffici
effector
function
rather
short
termin
halfliv
furthermor
mous
antibodi
found
induc
sever
immun
respons
human
rev
see
carter
develop
innov
recombin
dna
technolog
includ
chimera
humanis
mous
antibodi
molecul
greatli
enhanc
clinic
effici
safeti
murinederiv
monoclon
antibodi
almost
year
phage
display
use
select
specif
antigenbind
artifici
librari
singl
chain
antibodi
filament
phage
develop
carri
genet
inform
express
foreign
protein
surfac
assur
coupl
phenotyp
genotyp
phage
amplif
affin
select
abil
gener
larg
antibodi
librari
simplifi
antibodybackbon
singl
chain
antibodi
made
antibodyphag
display
power
tool
develop
new
therapeut
agent
rev
see
hoogenboom
et
al
kontermann
duebel
winter
et
al
parallel
new
evolv
molecular
strategi
help
enhanc
affin
stabil
express
level
boder
et
al
hane
et
al
rev
see
kurtzman
et
al
low
et
al
high
cost
antibodi
product
mammalian
system
limit
wider
use
antibodi
therapeut
scott
problem
essenti
import
applic
antibodi
therapeut
veterinari
medicin
product
shortfal
high
cost
provid
impetu
develop
altern
antibodi
product
technolog
chadd
chamow
fischer
et
al
kipriyanov
le
gall
infecti
diseas
rise
worldwid
estim
recognis
speci
human
pathogen
zoonot
ie
infect
one
host
zoonot
pathogen
repres
like
sourc
emerg
reemerg
infecti
diseas
woolhous
gowtagesequeria
thu
provid
solut
wellb
anim
also
impact
human
health
worldwid
dramat
increas
resist
antibiot
possibl
presenc
residu
meat
milk
egg
environ
spur
develop
altern
product
treatment
infecti
diseas
attempt
especi
made
reduc
quantiti
antibiot
use
prophylaxi
growth
promot
effect
anim
activ
vaccin
use
live
virul
attenu
vaccin
wide
use
drawback
term
low
level
immunogen
high
product
cost
antigen
variabl
speci
possibl
transfer
genet
materi
wildtyp
strain
vaccin
also
feasibl
option
mammal
postwean
well
anim
broiler
short
lifespan
product
vaccin
veterinari
use
also
need
low
cost
system
combin
inexpens
applic
strategi
ideal
express
system
recombin
antibodi
antigen
therefor
amen
genet
modif
inher
safe
econom
provid
function
protein
either
high
antibodi
affin
andor
neutralis
vaccin
capac
fischer
schillberg
system
product
antigen
antibodi
transgen
plant
develop
last
year
rev
see
gid
et
al
hood
et
al
koprowski
et
al
stoger
et
al
streatfield
streatfield
howard
warzecha
mason
plant
offer
gener
advantag
term
product
scale
economi
product
safeti
eas
storag
distribut
et
al
focu
product
vaccin
therapeut
antibodi
transgen
plant
veterinari
applic
recent
develop
plantibodi
plantigen
applic
veterinari
medicin
summaris
discuss
advantag
disadvantag
differ
plant
express
system
veterinari
applic
also
consid
econom
issu
develop
improv
vaccin
suitabl
way
combat
infecti
diseas
wild
also
domest
anim
current
strategi
use
intact
inactiv
pathogen
strain
induc
immun
well
subunit
vaccin
commerci
produc
bacteria
yeast
mammalian
cell
cultur
key
patent
curtiss
cardineau
describ
express
streptococcu
mutan
surfac
protein
antigen
spaa
transgen
tobacco
plant
curtiss
cardineau
subsequ
key
event
mason
cowork
succeed
express
hepat
b
surfac
antigen
tobacco
mason
et
al
usha
cowork
express
peptid
repres
epitop
envelop
protein
footandmouthdiseas
viru
fmdv
surfac
plant
viru
particl
usha
et
al
follow
pioneer
work
variou
veterinari
candid
vaccin
produc
use
engin
plant
virus
transgen
plant
overview
present
reflect
current
situat
plantbas
vaccin
focu
veterinari
applic
summari
plantbas
vaccin
veterinari
well
human
medicin
publish
streatfield
howard
joensuu
one
major
prerequisit
vaccin
product
planta
develop
fast
reliabl
safe
system
gener
transgen
plant
sinc
first
report
success
transform
plant
cell
fraley
et
al
variou
plant
express
system
establish
molecular
farm
rev
see
fischer
schillberg
stoger
et
al
b
four
differ
method
gener
use
product
recombin
protein
horn
et
al
gener
stabl
nuclear
transgen
plant
transplastom
plant
transient
express
use
plant
viru
transient
express
via
agrobacterium
infiltr
product
plant
releas
vaccin
hydropon
medium
compon
root
exud
anoth
possibl
product
system
impract
due
high
dilut
vaccin
technic
facil
requir
plant
cultiv
model
plant
arabidopsi
thaliana
tabl
tobacco
tabl
strong
candid
initi
studi
gener
stabl
transgen
plant
express
protein
interest
speci
edibl
leav
eg
lettuc
tabl
alfalfa
tabl
white
clover
tabl
tubersfruit
eg
potato
tabl
tomato
tabl
grain
eg
maiz
tabl
barley
tabl
also
use
product
veterinari
vaccin
oral
deliveri
offer
eas
applic
via
induct
mucos
immun
protect
pathogen
interact
host
mucos
surfac
rev
see
streatfield
contrast
immunis
anim
via
inject
predominantli
result
system
immun
respons
transient
express
method
use
plant
virus
establish
yield
high
level
protein
accumul
host
plant
rapid
amplif
infecti
plant
viral
genom
tabl
report
antigen
peptid
fuse
code
sequenc
viral
coat
protein
obtain
viruslik
particl
present
desir
peptid
result
virion
easili
purifi
centrifug
transplastom
plant
develop
improv
accumul
recombin
protein
shown
antigen
peptid
capsid
protein
canin
parvoviru
cpv
peptid
express
ntermin
translat
fusion
gu
protein
nucleartransform
arabidopsi
plant
rather
low
level
gil
et
al
peptid
fuse
gfp
cholera
toxin
b
subunit
accumul
tobacco
chloroplast
significantli
higher
level
compar
stabl
transform
tabl
exampl
success
product
transplastom
plant
heatlabil
toxin
b
subunit
tabl
candid
vaccin
enterotoxigen
escherichia
coli
etec
protect
antigen
bacillu
anthraci
tabl
advantag
chloroplast
transform
review
daniel
et
al
maliga
addit
exampl
cite
earlier
numer
veterinari
candid
vaccin
mainli
viru
infect
express
plant
exampl
footandmouthdiseas
viru
tabl
newcastl
diseas
viru
tabl
rinderpest
viru
tabl
rotaviru
tabl
complet
antigen
protein
well
peptid
repres
major
antigen
determin
produc
plant
system
case
vaccin
virus
protein
locat
virion
surfac
gener
suitabl
target
effici
immun
respons
vaccin
newcastl
diseas
viru
ndv
gener
base
plant
express
system
fusion
protein
f
hemagglutininneuraminidas
hn
ndv
initi
infect
process
essenti
target
host
immun
respons
neutralis
epitop
protein
select
express
use
plant
viru
system
tabl
complet
fusion
protein
f
also
form
transgen
maiz
plant
tabl
strategi
express
viru
protein
use
produc
differ
target
induct
adequ
host
immun
respons
tabl
wherea
certain
epitop
viral
protein
antigen
properti
select
case
tabl
addit
bacteri
infector
also
chosen
target
recombin
vaccin
eg
b
anthraci
tabl
e
coli
tabl
tuberculosi
tabl
sever
bacteri
pathogen
list
tabl
could
also
infect
human
therefor
describ
veterinari
plantderiv
vaccin
use
tool
human
medicin
b
anthraci
e
coli
tuberculosi
exampl
anim
pathogen
also
infect
human
eg
salmonella
avian
flu
especi
latter
attract
notic
plantbas
express
platform
near
futur
antigen
immunolog
potenti
identifi
vaccin
bacteri
diseas
eg
kda
earli
secret
antigen
target
case
tuberculosi
tabl
fimbrial
antigen
enterotoxigen
e
coli
strain
tabl
vaccin
etec
heatlabil
toxin
subunit
b
ltb
also
known
carrier
molecul
act
immunogen
produc
plant
tabl
anoth
interest
approach
obtain
plantbas
vaccin
coliform
mastiti
caus
e
coli
express
bovin
receptor
tabl
receptor
occur
membranebound
solubl
form
latter
bind
lipopolysaccharid
lp
outer
membran
eg
e
coli
induc
secret
cytokin
follow
host
innat
immun
respons
tabl
pathogen
b
anthraci
primarili
infect
anim
human
also
suscept
bacterium
candid
develop
biolog
weapon
identifi
categori
agent
bioterror
protect
antigen
pa
b
anthraci
use
immunis
anim
human
candid
vaccin
express
use
differ
plant
system
tabl
express
level
veterinari
vaccin
plant
crucial
econom
success
strategi
sinc
cost
product
applic
low
respect
express
level
candid
vaccin
summaris
tabl
gener
adequ
except
express
peptid
fuse
gfp
ltb
tobacco
chloroplast
tabl
case
express
level
calcul
approx
total
solubl
protein
approx
fusion
translat
fusion
report
eg
tabl
structur
protein
rhdv
fuse
ubiquitin
rbc
unfortun
express
level
rather
low
total
solubl
protein
without
fusion
ubiquitin
fusion
low
cost
applic
plantbas
vaccin
achiev
either
oral
deliveri
crude
plant
materi
edibl
vaccin
develop
simpl
purif
method
purif
detail
plantbas
veterinari
vaccin
larg
scale
publish
yet
hint
purif
plant
viru
particl
express
antigen
epitop
use
centrifug
tabl
veterinari
subunit
vaccin
use
either
affin
chromatographi
tabl
anion
exchang
chromatographi
tabl
small
scale
plantderiv
veterinari
vaccin
shown
tabl
test
laboratori
anim
either
inject
tabl
oral
deliveri
tabl
tabl
determin
abil
provok
humor
mucos
immun
respons
mention
induct
mucos
antibodi
epitop
certain
pathogen
especi
favour
oral
deliveri
plantderiv
recombin
vaccin
pathogen
enter
colonis
host
via
mucos
surfac
gastrointestin
respiratori
genit
tract
combat
infector
mucos
vaccin
induc
gener
serum
igg
mucos
antibodi
iga
need
achiev
oral
deliveri
eg
transgen
peanut
leav
express
rinderpest
viru
hemagglutinin
protein
h
mice
tabl
splenocyt
collect
week
postor
immunis
prolifer
presenc
specif
antigen
immun
respons
h
protein
studi
cattl
tabl
also
system
immun
respons
induc
upon
oral
deliveri
oral
immunis
plantderiv
rotaviru
capsid
protein
induc
serum
igg
mucos
iga
mice
tabl
function
activ
antirotaviru
intestin
antibodi
could
detect
faec
mice
immunis
transgen
potato
tuber
express
capsid
protein
tabl
oral
immunis
femal
mice
rotaviru
capsid
protein
result
reduc
symptom
offspr
viru
challeng
tabl
passiv
transfer
antirotaviru
antibodi
immunis
dam
offspr
protect
pup
viru
challeng
observ
tabl
cornbas
vaccin
porcin
transmiss
gastroenter
viru
ptgev
boost
antibodi
level
serum
colostrum
milk
immunis
gilt
indic
immun
passiv
transfer
suckl
piglet
tabl
detect
immun
respons
deliv
plantbas
candid
vaccin
observ
everi
case
tabl
recombin
protein
given
anim
viru
challeng
experi
show
protect
immunis
anim
tabl
howev
vaccin
rabbit
plantderiv
crpv
protein
complet
prevent
papilloma
growth
tabl
clinic
symptom
bhv
appear
later
milder
cow
vaccin
plantproduc
truncat
glycoprotein
tabl
demonstr
mice
immunis
plantderiv
protect
antigen
b
anthraci
surviv
challeng
lethal
dose
toxin
tabl
although
express
veterinari
vaccin
candid
differ
plant
speci
well
studi
immunogen
evalu
challeng
plantderiv
veterinari
vaccin
still
remain
barley
tabl
maiz
tabl
white
clover
tabl
alfalfa
tabl
constitut
main
compon
anim
feed
model
plant
routin
use
express
system
use
crop
plant
product
veterinari
vaccin
therefor
need
develop
purif
technolog
essenti
plantderiv
vaccin
administ
inject
develop
low
cost
purif
method
import
commerci
success
oral
deliveri
vaccin
larg
amount
recombin
protein
requir
increas
express
level
remain
major
challeng
especi
edibl
vaccin
multicompon
vaccin
eg
e
coli
fimbrial
antigen
combin
subunit
cholera
toxin
epitop
rotaviru
tabl
protect
anim
much
way
human
multipl
infecti
diseas
howev
also
requir
develop
reliabl
product
system
well
defin
dose
regimen
ultim
market
product
one
major
step
toward
market
plantderiv
vaccin
made
dow
agrosci
begin
tabl
obtain
feder
approv
us
vaccin
newcastl
diseas
viru
produc
tobacco
cell
cultur
regrett
chicken
vaccin
introduc
market
yet
http
view
spread
microbi
resist
antibiot
emerg
new
pathogen
passiv
immunis
recombin
antibodi
view
one
promis
altern
combat
infecti
diseas
casadeval
market
human
therapeut
monoclon
antibodi
grow
forecast
compound
annual
growth
rate
reach
billion
pavlou
belsey
market
heavili
focus
oncolog
arthriti
immun
inflammatori
diseas
role
antibodi
mitig
therapi
infecti
diseas
slowli
emerg
imped
high
cost
good
high
cost
good
recombin
antibodi
far
also
prevent
success
introduct
anim
health
market
plantbas
product
provid
solut
cost
problem
addit
plant
provid
adequ
system
oral
deliveri
recombin
biomolecul
part
diet
infrastructur
cost
downstream
process
thu
avoid
well
product
loss
often
signific
proofofconcept
express
recombin
antibodi
antibodi
fragment
plant
demonstr
late
hiatt
et
al
sinc
differ
moieti
gener
rang
singl
chain
molecul
scfv
fab
fragment
small
immun
protein
sip
igg
chimer
secretori
iga
rev
see
et
al
despit
progress
product
antibodi
plant
human
health
applic
veterinari
field
rather
limit
potenti
product
develop
focus
vaccin
see
earlier
howev
recent
encourag
develop
report
field
passiv
immunis
focu
gener
develop
product
oral
applic
product
anim
prevent
andor
therapi
major
commerci
relev
infecti
diseas
studi
goal
appli
antibodi
molecul
oral
limit
purif
thu
make
product
compat
alreadi
place
cost
structur
market
anim
product
one
major
hurdl
low
concentr
heterolog
protein
plant
tissu
effort
overcom
limit
address
literatur
littl
attent
far
given
issu
final
product
formul
efficaci
longterm
stabil
farm
condit
far
scfv
scfv
fusion
protein
iga
iga
fusion
protein
express
transgen
tobacco
cowpea
well
use
transient
viral
system
rev
see
fischer
et
al
sever
exampl
present
detail
work
borderlin
anim
human
health
biodefens
almquist
cowork
transform
tobacco
synthet
optimis
gene
scfv
botulinum
neurotoxin
almquist
et
al
singl
chain
antibodi
bind
lipopolysaccharid
lp
salmonella
enterica
paratyphi
b
express
tobacco
makvandinejad
et
al
scfv
develop
higher
affin
introduc
two
point
mutat
result
format
dimer
multim
deng
et
al
earlier
find
confirm
tobacco
differ
line
differ
function
structur
properti
scfv
observ
investig
transmiss
gastroenter
viru
tgev
coronaviru
caus
near
mortal
newborn
piglet
enjuan
van
der
zeijst
tgevspecif
small
immun
protein
sip
express
nicotiana
clevelandii
cowpea
vigna
undulata
oral
applic
monger
et
al
sip
dimer
fusion
domain
human
ige
scfv
antibodi
specif
tgev
stabilis
ctermin
cystein
residu
express
achiev
agrobacteria
inocul
two
differ
viral
vector
base
potato
viru
x
pvx
cowpea
mosaic
viru
cpmv
effect
dimeris
capac
bind
neutralis
tgev
vitro
demonstr
crude
plant
extract
contain
oral
appli
totwoday
old
piglet
togeth
tgev
challeng
result
reduct
viru
titr
gut
lung
observ
although
lower
extent
fulllength
mammalian
produc
parent
monoclon
antibodi
subsequ
report
group
iga
deriv
sip
contain
domain
iga
lack
stabilis
ctermin
cystein
express
plant
togeth
fulllength
recombin
iga
alamillo
et
al
cpmv
pvx
inocul
use
express
sip
wherea
recombin
iga
express
use
pvx
system
effect
dimeris
recombin
iga
demonstr
express
level
gener
low
differ
vector
effici
observ
express
time
higher
cpmv
system
wherea
express
higher
use
pvx
vector
crude
plant
extract
contain
either
recombin
iga
administ
oral
newborn
piglet
tgev
challeng
notabl
reduct
viru
titr
observ
fulllength
recombin
iga
reduc
viru
titr
lung
gut
contrast
recombin
iga
almost
ineffect
lung
highli
effect
gut
although
activ
gener
lower
parent
monoclon
antibodi
differ
tissu
specif
activ
explain
smaller
size
allow
higher
tissu
penetr
howev
adjuv
effect
plant
extract
rule
coccidiosi
commerci
relev
infecti
diseas
chicken
caus
intracellular
protozoan
parasit
belong
genu
eimeria
recombin
chicken
iga
propos
potenti
mean
passiv
immunis
diseas
wieland
et
al
iga
chosen
assum
role
protect
mucos
surfac
similar
mammalian
iga
set
ten
fulllength
chicken
iga
cdna
clone
agrobacterium
vector
transient
express
tobacco
n
benthamiana
coinfiltr
two
differ
vector
contain
gene
code
igl
ighalpha
chain
function
fullsiz
antibodi
proven
elisa
assay
eimeria
antigen
larg
differ
found
product
level
differ
immunoglobulin
plant
poor
without
express
shown
low
nondetect
igl
level
clone
degrad
ighalpha
chain
show
low
light
chain
express
even
express
light
chain
like
light
chain
stabilis
fulllength
heavi
chain
prevent
degrad
thu
express
light
chain
might
limit
factor
assembl
stabil
plantmad
chicken
iga
coinfiltr
experi
demonstr
capac
plant
cell
assembl
chicken
secretori
iga
complex
dimer
iga
diga
complex
includ
j
chain
also
associ
diga
chicken
secretori
compon
although
result
discuss
rather
preliminari
increas
evid
oral
appli
recombin
antibodi
capac
reduc
infecti
load
anim
follow
oral
administr
issu
stabil
gut
tissu
penetr
clearanc
gener
immunogen
effect
address
well
technic
issu
commerci
applic
current
result
indic
gener
applic
ideal
plant
system
express
antibodi
antibodi
fragment
system
must
care
chosen
tailor
specif
type
even
specif
sequenc
antibodi
studi
effici
transform
regener
plant
major
prerequisit
develop
suitabl
express
system
vaccin
therapeut
antibodi
system
avail
model
plant
tobacco
arabidopsi
also
develop
crop
maiz
rice
barley
pea
potato
tomato
alfalfa
lettuc
outlin
section
plantderiv
vaccin
veterinari
purpos
therapeut
antibodi
veterinari
use
transgen
plant
mani
differ
transform
system
success
appli
veterinari
purpos
includ
viral
system
develop
also
need
consid
product
safeti
plant
contain
human
pathogen
oncogen
dna
microbi
endotoxin
may
contain
pesticid
residu
possibl
contamin
specif
plant
may
compris
sever
toxic
secondari
metabolit
toxin
deriv
plant
pathogen
remov
substanc
purif
process
includ
final
proof
absenc
inevit
increas
cost
crop
current
use
anim
feed
provid
alreadi
proven
safe
altern
equival
gra
statu
food
crop
develop
rather
simpl
procedur
downstream
process
formul
scale
essenti
veterinari
applic
method
invers
transit
cycl
use
elastinlikepeptid
fusion
exampl
low
cost
larg
scale
purif
scheme
scheller
et
al
major
advantag
crop
plant
easi
upscal
field
cultiv
establish
harvest
process
technolog
howev
increas
cost
due
qualiti
control
qualiti
assur
regulatori
surveil
also
taken
account
easi
storag
distribut
key
advantag
molecular
farm
achiev
seedspecif
express
highlevel
product
longterm
storag
antibodi
seed
shown
year
ago
fiedler
conrad
stoger
et
al
vaccin
product
seed
also
outlin
sever
exampl
tabl
view
major
issu
term
reduc
cost
maximis
econom
valu
adequ
product
level
planta
increas
express
level
particularli
seed
directli
improv
econom
valu
veterinari
product
molecular
pharm
applic
lead
decreas
cost
plant
qualiti
control
harvest
storag
new
promot
regulatori
sequenc
well
fusion
specif
peptid
improv
accumul
transgen
protein
seed
de
jaeger
et
al
scheller
et
al
techniqu
appli
develop
new
product
vaccin
well
therapeut
antibodi
high
demand
new
specif
product
spur
ban
persist
drug
especi
antibiot
catalys
develop
therapeut
proteinbas
treatment
veterinari
medicin
molecular
pharm
provid
better
solut
